EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world incidence of cancer therapy–related cardiac dysfunction in a large, diverse, and contemporary cohort

Samir R Thadani iD, Alan S Go, Jane Y Liu, Rishi V Parikh iD, Elisha A Garcia, Elizabeth M Cespedes Feliciano iD, Ankeet S Bhatt iD, Sirtaz Adatya, Marilyn L Kwan iD, Amy Y Lin, Raymond Liu iD, Alfredo Lopez und 5 weitere

ESC Heart Failure · 2026

DOI: 10.1093/eschf/xvag113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2026. Verfasst von Samir R Thadani und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Kaiser Permanente South SanFrancisco Medical Center, 1200 El Camino Real, South San Francisco, CA 94080, USA. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Stroke Volume, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Permanente Medical Group (TPMG) Delivery Science Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Cancer therapy–related cardiac dysfunction (CTRCD) is a complication of contemporary oncologic treatment and a contributor to incident heart failure (HF) in cancer survivors. Although certain potentially cardiotoxic cancer therapies are known to increase risk, population-based estimates in large, diverse, and contemporary cohorts remain limited. The aim of the Kaiser Permanente Cardiovascular Health Enhancement and Monitoring for Oncology (KP CHEMO) study was to determine the incidence, timing, and treatment-specific variation in CTRCD within an integrated US health system. Methods and Results We conducted a retrospective cohort study of adult Kaiser Permanente Northern California (KPNC) members diagnosed with malignant tumours between 2012 and 2022 who received anthracyclines, human epidermal growth factor receptor (HER2) inhibitors, immune checkpoint inhibitors (ICIs), or tyrosine kinase inhibitors. CTRCD was defined as a >10% decline in left ventricular ejection fraction to <53% or incident HF identified by natural language processing. Cumulative incidence rates were calculated overall and by drug class. Early CTRCD was ≤12 months and late was >12 months. Among 26 646 patients (mean age 62 ± 14 years; 64% women; 57% non-Hispanic White), the cumulative incidence of CTRCD was 8.4% (95% confidence interval 7.7–9.1). Incidence was highest with HER2 inhibitors (10.7%) and lowest with ICIs (5.2%) (P < .001). Nearly half of all events occurred within the first year. Conclusions CTRCD was common and occurred predominantly within the first year after therapy initiation, potentially reflecting both early susceptibility and more intensive early surveillance. Variation across drug classes highlights differing cardiotoxic risk profiles. These findings support risk prediction models and targeted surveillance strategies to reduce downstream HF risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsStroke VolumeHeart FailureHumansFemaleIncidenceRetrospective StudiesMiddle AgedMaleCardiotoxicityCaliforniaAgedRisk FactorsFollow-Up Studies

Stichwörter der Autor:innen

Cancer therapy–related cardiac dysfunctionCardio-oncologyChemotherapyHeart failure

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Cardiology, Kaiser Permanente South SanFrancisco Medical Center, 1200 El Camino Real, South San Francisco, CA 94080, USA.
  • Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
  • Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
  • Departments of Epidemiology, Biostatistics and Medicine, University of California, SanFrancisco, San Francisco, CA USA.
  • Department of Cardiology, Kaiser Permanente SanFrancisco Medical Center, San Francisco, CA, USA.
  • Department of Cardiology, Kaiser Permanente Santa Clara, Santa Clara, CA, USA.

ORCID-Profile: Samir R Thadani, Rishi V Parikh, Elizabeth M Cespedes Feliciano, Ankeet S Bhatt, Marilyn L Kwan, Raymond Liu, Joshua R Nugent, David Ouyang, Andrew P Ambrosy

Förderung

  • The Permanente Medical Group (TPMG) Delivery Science Program

Zitieren

APA

Thadani, S. R., Go, A. S., Liu, J. Y., Parikh, R. V., Garcia, E. A., Cespedes Feliciano, E. M., Bhatt, A. S., Adatya, S., Kwan, M. L., Lin, A. Y., Liu, R., Lopez, A., Nugent, J. R., Ouyang, D., Yen, A. H., Zaroff, J. G., & Ambrosy, A. P. (2026). Real-world incidence of cancer therapy–related cardiac dysfunction in a large, diverse, and contemporary cohort. ESC Heart Failure. https://doi.org/10.1093/eschf/xvag113

Vancouver

Thadani SR, Go AS, Liu JY, Parikh RV, Garcia EA, Cespedes Feliciano EM, et al. Real-world incidence of cancer therapy–related cardiac dysfunction in a large, diverse, and contemporary cohort. ESC Heart Failure. 2026. doi:10.1093/eschf/xvag113

BibTeX
@article{Thadani2026,
  author = {Thadani, Samir R and Go, Alan S and Liu, Jane Y and Parikh, Rishi V and Garcia, Elisha A and Cespedes Feliciano, Elizabeth M and Bhatt, Ankeet S and Adatya, Sirtaz and Kwan, Marilyn L and Lin, Amy Y and Liu, Raymond and Lopez, Alfredo and Nugent, Joshua R and Ouyang, David and Yen, Alberta H and Zaroff, Jonathan G and Ambrosy, Andrew P},
  title = {Real-world incidence of cancer therapy–related cardiac dysfunction in a large, diverse, and contemporary cohort},
  journal = {ESC Heart Failure},
  year = {2026},
  doi = {10.1093/eschf/xvag113}
}
Kostenlos starten →